Pharmaceutical and biomedical applications of lipid-based nanocarriers [0.03%]
基于脂质的纳米载体在药物和生物医学领域的应用
Claudia Carbone,Antonio Leonardi,Sarha Cupri et al.
Claudia Carbone et al.
Increasing attention is being given to lipid nanocarriers (LNs) as drug delivery systems, due to the advantages offered of a higher biocompatibility and lower toxicity compared with polymeric nanoparticles. Many administration routes are be...
Roxanne P Spencer
Roxanne P Spencer
As a case study of patent coverage for a repurposed drug, Biogen Idec's approach for Tecfidera(®), an oral formulation of dimethyl fumarate, was analyzed. While mixtures of fumarates have been used for over 50 years to treat psoriasis, Tec...
Paolo Pevarello,Silvia Cainarca,Chiara Liberati et al.
Paolo Pevarello et al.
Ca(2+) release-activated Ca(2+) (CRAC) channels are becoming important targets for therapeutic intervention in several areas of disease, including immunology, allergy and cancer. In parallel to the progression towards reliable methods for m...
Scott Parker,Ben Hall
Scott Parker
In this review, we take a look at the patentability issues surrounding personalized medicine patent claims. We examine how the USA and European Patent Office have dealt with such patent claims, and then review the UK 'inherency' and 'select...
Crystalline forms of nonprotein drugs filed in Brazil from 1995-2005 [0.03%]
1995至2005年巴西注册的非蛋白质药物结晶型形式 khảo cứu专注于1995年至2005年间在巴西注册的非蛋白质类药物的结晶型形式。
Luiz Marcelo Lira,Luiz Cláudio Rodrigues Pereira da Silva,Antônio J Ribeiro et al.
Luiz Marcelo Lira et al.
In the present study, we evaluated 457 patent applications filed for crystalline forms of nonprotein drugs during the period 1995-2005 in Brazil. Online searches were conducted using the Instituto Nacional da Propriedade Industrial patent d...
Changes in global pharmaceutical patent strategy due to intergovernmental cooperation [0.03%]
政府间合作引发的全球药品专利战略变化分析
Takeshi S Komatani
Takeshi S Komatani
Inter partes review: considerations for abbreviated new drug application cases [0.03%]
简化新药申请案中_inter_partes_复审考量因素分析
Patricia Carson,Scott Taylor
Patricia Carson
Regulatory exclusivity in the EU: the impact of new active substance status [0.03%]
欧盟的监管排他性：新活性物质身份的影响
Peter Bogaert,Sarah Forest
Peter Bogaert
The Indian Supreme Court's judgment in the case of Glivec(®) - the uncertain future of pharmaceutical patents in India [0.03%]
印度最高法院对Glivec案件的判决——印度药品专利不确定的未来
Prashant Reddy Thikkavarapu
Prashant Reddy Thikkavarapu